ClinVar Miner

Submissions for variant NM_007294.3(BRCA1):c.1924G>T (p.Asp642Tyr) (rs80357344)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 1
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
GeneDx RCV000522342 SCV000616657 uncertain significance not provided 2017-07-28 criteria provided, single submitter clinical testing This variant is denoted BRCA1 c.1924G>T at the cDNA level, p.Asp642Tyr (D642Y) at the protein level, and results in the change of an Aspartic Acid to a Tyrosine (GAT>TAT) in exon 10. This variant has not, to our knowledge, been published in the literature as either a pathogenic variant or a benign polymorphism. BRCA1 Asp642Tyr was not observed in approximately 6,500 individuals of European and African American ancestry in the NHLBI Exome Sequencing Project, indicating it is not a common benign variant in these populations. Since Aspartic Acid and Tyrosine differ in polarity, charge, size or other properties, this is considered a non-conservative amino acid substitution. BRCA1 Asp642Tyr alters a position that is moderately conserved in mammals and is located in the DNA binding domain (Narod 2004). In silico analyses are inconsistent regarding the effect this variant may have on protein structure and function. Based on currently available information, it is unclear whether BRCA1 Asp642Tyr is a pathogenic or a benign

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.